Advanced NSCLC Clinical Trial
Official title:
A Phase 1/2 Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Patients With MET Overexpressing Advanced Cancer
This study is researching an experimental drug called REGN5093-M114 by itself and in combination with cemiplimab. The study is focused on advanced non-small cell lung cancer (NSCLC) that produces too much of a protein called mesenchymal epithelial transition factor (MET) on the cancer cell surface. The aim of the study is to see how safe, tolerable, and effective the study drug is. This study will include 3 study groups, or cohorts, and each group is split into 2 parts: Part 1: The main purpose of part 1 is to determine a safe dose of REGN5093-M114 (Cohorts A and B), and in combination with cemiplimab (Cohort C). Part 2: The main purpose of part 2 is to use the REGN5093-M114 dose found for each cohort in part 1 to see how well the study drug works to shrink tumors. The study is looking at several other research questions, including: - What side effects may happen from receiving the study drug - Does the study drug work to reduce or delay the progression of your cancer - How much study drug is in the blood at different times - Does the body make antibodies against the study drug (which could make the drug less effective or could lead to side effects)
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02133196 -
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT00813332 -
Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)
|
Phase 4 | |
| Completed |
NCT03215810 -
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT04992858 -
Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations
|
Phase 2 | |
| Active, not recruiting |
NCT03127449 -
AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
|
N/A | |
| Recruiting |
NCT05609578 -
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
|
Phase 2 | |
| Not yet recruiting |
NCT06356675 -
A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy
|
Phase 4 | |
| Completed |
NCT03074175 -
Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01)
|
N/A | |
| Terminated |
NCT05106335 -
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
|
Phase 3 | |
| Not yet recruiting |
NCT04229121 -
Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
|
||
| Recruiting |
NCT05219162 -
Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).
|
Phase 4 | |
| Not yet recruiting |
NCT05859217 -
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
|
Phase 2 | |
| Recruiting |
NCT03062800 -
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
|
Phase 2 | |
| Completed |
NCT02055508 -
POSITIVE - Study (Part III) Heidelberg
|
N/A | |
| Active, not recruiting |
NCT04043195 -
Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
|
Phase 1/Phase 2 |